Inhibiting an intestinal nuclear receptor using tempol and antibiotics appears to be a promising treatment for nonalcoholic fatty liver disease (NAFLD). Research by scientists at Penn State University confirmed earlier findings that tempol and antibiotics may reduce some types of Lactobacillus, which in turn increases production of tauro-beta-muricholic acid that directly inhibits the intestinal farnesoid X receptor (FXR). In their experiments on mice, tempol plus bacitracin, neomycin, and streptomycin directly inhibited the FXR and regulated the metabolism of bile acids, fats, and glucose when the mice were fed a high-fat diet designed to induce NAFLD. Next steps include studies on humans and investigations into possible adverse effects from the modulation of bacteria in the digestive system and FXR via this treatment.
READ FULL ARTICLE From Edu